AU · rank #3 · 2026-09-10
PGEN
NASDAQ · $2.43B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.892 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.48 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $24,662 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $14.50 | +113.2% |
| Momentum acceleration 3-month minus 12-month momentum. | +36.14% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 3.75 |
| Gross margin TTM | +53.0% |
| 52w high | $7.72 |
| Market cap (USD) | $2.43B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Precigen is a clinical-stage biotech that achieved its first profitable quarter in Q2 2026 driven by rapidly accelerating PAPZIMEOS sales ($53.1M, >2x sequential growth) for recurrent respiratory papillomatosis.
Rationale
The 113% analyst upside, 100% revision agreement, and a 475% earnings surprise all converge on a genuine commercial inflection that the analyst_upside strategy is designed to capture — the signal is grounded in real revenue, not sentiment alone.
Material risks
- 1Coverage is only 3 analysts with zero net upgrades or target raises in 30/90 days, meaning the 113% implied upside reflects stale targets that haven't been revised up post-beat, raising the risk that consensus catches up via target raises rather than price appreciation.
- 2PAPZIMEOS addresses a rare disease with a finite addressable population, so revenue growth must decelerate as the prevalent pool is treated, and pipeline assets (PRGN-3006, PRGN-2009) remain early-stage with binary trial risk.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.